Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (CF) (2021 - 2025)
Historic Depreciation & Amortization (CF) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $100000.0.
- Amylyx Pharmaceuticals' Depreciation & Amortization (CF) fell 5000.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $600000.0, marking a year-over-year decrease of 4005.99%. This contributed to the annual value of $900000.0 for FY2024, which is 1818.18% down from last year.
- Per Amylyx Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $100000.0 for Q3 2025, which was down 5000.0% from $100000.0 recorded in Q2 2025.
- Amylyx Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $302000.0 during Q3 2023, with a 5-year trough of $10000.0 in Q1 2021.
- For the 5-year period, Amylyx Pharmaceuticals' Depreciation & Amortization (CF) averaged around $154052.6, with its median value being $182000.0 (2022).
- In the last 5 years, Amylyx Pharmaceuticals' Depreciation & Amortization (CF) surged by 155000.0% in 2022 and then plummeted by 5000.0% in 2025.
- Amylyx Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $22000.0 in 2021, then skyrocketed by 727.27% to $182000.0 in 2022, then skyrocketed by 65.38% to $301000.0 in 2023, then tumbled by 33.55% to $200000.0 in 2024, then tumbled by 50.0% to $100000.0 in 2025.
- Its Depreciation & Amortization (CF) stands at $100000.0 for Q3 2025, versus $100000.0 for Q2 2025 and $200000.0 for Q1 2025.